UNSPSC 51334502: Butaclamol

This classification denotes a dopamine antagonist with the molecular formula C25H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7A2802VNL, chemically known as 1h-benzo(6,7)-cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3alpha,4aalpha,13bbeta)-(+-)- but generally known as butaclamol, which bears US NIH Compound Identifier 37459. Butaclamol most often comes in base and hydrochloride forms.

UNSPSC 51334502 Butaclamol is a Commodity code that does not align with recent state and local procurement activity posted under this designation. The three recent opportunities tagged to this code — a Seminole County naloxone and drug deactivation systems bid, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions, and a Minnesota multistate cooperative pharmaceuticals RFP — involve naloxone distribution, pharmacy benefit program design, and generic multi-source pharmaceutical supply respectively. None of these solicitations name or reference butaclamol as a procured product or service line. The mismatch suggests either a tagging error in the source data or that butaclamol does not currently drive state and local procurement activity in the available recent records.

State and local governments are actively soliciting pharmaceutical products and pharmacy-related services under nearby taxonomy codes, as evidenced by Seminole County's July 2026 IFB for naloxone and drug deactivation systems (response deadline July 26, 2026), the Texas HHS Commission's April 2026 RFI on direct-to-manufacturer prescription programs, and the Minnesota MMCAP's March 2026 RFP for generic pharmaceuticals and OTC products serving multi-state participating agencies. These opportunities span county health departments, state health agencies, and cooperative purchasing alliances, with geographic activity in Florida, Texas, and Minnesota. However, none of these procurements appear to involve butaclamol specifically, limiting the code's relevance for current business development purposes under its stated commodity designation.